Avantor's robust business model yields stable cash flows and generates sticky customers. Avantor’s leadership in the biopharma industry and shifting revenue mix can produce considerable margin ...
Avantor (NYSE:AVTR) is gearing up to announce its quarterly earnings on Friday, 2024-10-25. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...
Avantor is a turnaround play in life sciences distribution and manufacturing, trading at a historically low valuation after a 50% stock decline. New management is executing a Revival program targeting ...
11 analysts have shared their evaluations of Avantor (NYSE:AVTR) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed view of their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results